Theravance Biopharma, Inc.TBPHNASDAQ
Loading
Cost of Revenue Over TimeContracting
Percentile Rank57
3Y CAGR-55.7%
Studio
Year-over-Year Change

Direct costs attributable to producing goods sold

3Y CAGR
-55.7%/yr
vs +206.9%/yr prior
Acceleration
-262.5pp
Decelerating
Percentile
P57
Within normal range
vs 3Y Ago
0.1x
Contraction
Streak
1 yr
Consecutive growthContracting
PeriodValueYoY Change
TTM$5.51M-
2024$0.00-100.0%
2023$40.62M-35.9%
2022$63.39M-67.3%
2021$193.66M-
2020$0.00-
2019$0.00-100.0%
2018$715000.00-88.1%
2017$6.03M+108.4%
2016$2.89M-